BidaskClub upgraded shares of Neurocrine Biosciences (NASDAQ:NBIX) from a sell rating to a hold rating in a report issued on Thursday morning.
Other equities analysts have also issued reports about the stock. Canaccord Genuity began coverage on shares of Neurocrine Biosciences in a report on Wednesday, November 21st. They issued a buy rating and a $111.00 price target on the stock. Oppenheimer set a $105.00 price target on shares of Neurocrine Biosciences and gave the stock a buy rating in a report on Tuesday, January 29th. Needham & Company LLC set a $104.00 price objective on shares of Neurocrine Biosciences and gave the company a buy rating in a report on Wednesday, December 12th. Robert W. Baird dropped their price objective on shares of Neurocrine Biosciences from $131.00 to $96.00 and set an outperform rating on the stock in a report on Thursday, December 13th. Finally, HC Wainwright reissued a buy rating and set a $162.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, December 13th. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $102.56.
NASDAQ NBIX traded up $0.72 on Thursday, hitting $83.69. The stock had a trading volume of 48,263 shares, compared to its average volume of 992,142. The company has a current ratio of 8.36, a quick ratio of 8.24 and a debt-to-equity ratio of 0.81. Neurocrine Biosciences has a 52-week low of $64.72 and a 52-week high of $126.98. The firm has a market capitalization of $7.60 billion, a P/E ratio of 380.41, a P/E/G ratio of 29.63 and a beta of 1.86.
In related news, insider Kyle Gano sold 3,809 shares of the business’s stock in a transaction on Tuesday, February 5th. The shares were sold at an average price of $88.12, for a total transaction of $335,649.08. Following the completion of the transaction, the insider now directly owns 17,595 shares in the company, valued at $1,550,471.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kevin Charles Gorman sold 7,614 shares of the business’s stock in a transaction on Tuesday, February 5th. The shares were sold at an average price of $88.16, for a total transaction of $671,250.24. Following the transaction, the chief executive officer now owns 408,082 shares of the company’s stock, valued at $35,976,509.12. The disclosure for this sale can be found here. Insiders have sold 13,280 shares of company stock valued at $1,163,054 over the last 90 days. 4.30% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of NBIX. Acadian Asset Management LLC acquired a new position in shares of Neurocrine Biosciences in the fourth quarter worth about $32,000. Exane Derivatives raised its position in shares of Neurocrine Biosciences by 48,400.0% in the fourth quarter. Exane Derivatives now owns 485 shares of the company’s stock worth $35,000 after acquiring an additional 484 shares during the period. Rehmann Capital Advisory Group raised its position in shares of Neurocrine Biosciences by 54.7% in the third quarter. Rehmann Capital Advisory Group now owns 557 shares of the company’s stock worth $68,000 after acquiring an additional 197 shares during the period. Penserra Capital Management LLC acquired a new position in shares of Neurocrine Biosciences in the fourth quarter worth about $86,000. Finally, Arbor Wealth Management LLC acquired a new position in shares of Neurocrine Biosciences in the fourth quarter worth about $92,000.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Featured Story: Rule of 72
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.